Ebola Sudan Virus Disease
Conditions
Brief summary
A Phase 1, Single-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine at 3 Dose Levels in Adults in Good General Health
Detailed description
The purpose of this study is to provide the needed safety and immunogenicity data to support rapid deployment of the SEBOV vaccine against an ongoing or future outbreak. The intervention will be a single dose and will either be study vaccine named rVSVΔG-SEBOV-GP Vaccine, or placebo (a placebo is an inactive substance or other intervention that looks the same as and is given the same way as study vaccine or treatment being tested) There are 3 group in this study, each group has different vaccine doses. Group 1 starts with the lowest dose of the study vaccine and each subsequent group Groups 2 and Group 3 gets a higher dose of the study vaccine. Approximately 36 participants will be included in the study. The participant will be unaware of the treatment given between placebo and study vaccine. Participants will be screened up to 14 days before IP administration and will be followed for 6 months after IP administration. The anticipated study duration for each participant in Groups 1 through 3 is approximately 6.5 months from screening through last study visit.
Interventions
DRUGrVSV∆G-SEBOV-GP Vaccine or Placebo
rVSV∆G-SEBOV-GP Vaccine or Placebo
Sponsors
Biomedical Advanced Research and Development Authority
International AIDS Vaccine Initiative
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)
Masking description
It is a single blind study. The participant will be unaware of the intervention.
Intervention model description
This is a single-blind, placebo-controlled, dose-escalation clinical trial to evaluate the safety and immunogenicity of rVSVΔG-SEBOV-GP vaccine at 3 dose levels in adults in good general health.
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
Inclusion: * Good general health * ≥18 years of age on the day of screening and are ≤50 years of age on the day of IP administration * Adherence to the requirements of the protocol and the follow-up for the planned duration of the study * Undergo HIV testing, risk reduction counseling, and receive HIV test results * As applicable use male or female condoms for 1 month following IP administration * Use an effective method of contraception from at least 2 weeks before and continue until 3 months following receipt of vaccine * As applicable undergo urine pregnancy tests * Forgo donation of blood or any other tissues throughout the course of the study Exclusion: * Any clinically relevant abnormality * Any clinically significant acute or chronical medical condition * Women who are pregnant or breastfeeding * Bleeding disorder * Infectious disease * History of splenectomy * Receipt of any vaccine within the previous 28 days or planned receipt within 28 days after vaccination with IP. * Receipt of blood transfusion or blood-derived products within 3 months prior to screening * Prior exposure to SEBOV or history of any hemorrhagic fever * Prior receipt of any VSV-vectored vaccine * Receipt of another IP within 3 months prior to enrollment or expected participation during this study. * Prior receipt of another Sudan Ebola vaccine or receipt of polyclonal or monoclonal antibodies directed against Sudan Ebola in the past 6 months * History of severe reactogenicity to vaccines or severe allergy to food or medications * A history of malignancy in the past 5 years (prior to screening) or ongoing malignancy. * Serious infections requiring antibiotic, antiviral, or antifungal therapy within 30 days prior to enrollment * Body mass index (BMI) ≥35 * Current or planned occupational or household contact from screening through 3 months after vaccine administration with any immunocompromised individual
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the safety and tolerability of rVSVΔG-SEBOV-GP vaccine | 14 days | Proportion of participants with Grade 3 or higher reactogenicity (ie, solicited AEs) during the 14 days after vaccine administration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To determine SEBOV-GP-specific antibody responses induced by rVSVΔG-SEBOV-GP vaccine | 6.5 months | Proportion of participants with binding antibody responses to SEBOV-GP |
Other
| Measure | Time frame | Description |
|---|---|---|
| To explore the characteristics of the immune responses induced by rVSV∆G-SEBOV-GP vaccine | 6.5 months | Anti-GP IgG antibodies as measured in 'effector assays' such as ADCC |
Countries
United States
Outcome results
None listed